PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT · OTCMCIK 315545fmd_0KQXRV3817F2Y4MAN6VP6HCM7KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2002 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 1 | 1 | 1 | 0 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Net interest income | – | – | – | – | – | (1) | (0) | (0) | (0) | (0) |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 8 | 8 | 5 | 4 | 3 | 3 | 2 | 2 | 2 | 2 |
| Total operating expenses | – | – | 8 | 6 | 5 | 5 | 4 | 3 | 5 | 6 |
| Operating income | (25) | (13) | (8) | (6) | (5) | (5) | (3) | (3) | (5) | (5) |
| Interest expense | – | – | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | – | – | – | (1) | (2) | (1) | (0) | (0) | (0) | (0) |
| Income before taxes | – | (14) | (8) | (7) | (7) | (6) | (4) | (3) | (5) | (6) |
| Income tax expense | 0 | – | – | – | – | – | – | – | – | – |
| Net income | (24) | (14) | (8) | (7) | (7) | (6) | (4) | (3) | (5) | (5) |
| Net income to common shareholders | (29) | (14) | (8) | – | – | – | – | – | – | – |